Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has received an average rating of “Hold” from the seven brokerages that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $3.49.
Separately, Zacks Investment Research raised Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research report on Thursday, August 15th.
Conatus Pharmaceuticals stock traded up $0.02 during mid-day trading on Friday, hitting $0.34. 3,801 shares of the company’s stock were exchanged, compared to its average volume of 897,579. The stock has a market cap of $10.95 million, a P/E ratio of -0.57 and a beta of 2.18. Conatus Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $5.89. The stock has a 50 day moving average of $0.33 and a two-hundred day moving average of $0.60.
A hedge fund recently raised its stake in Conatus Pharmaceuticals stock. Acadian Asset Management LLC grew its holdings in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) by 90.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 467,425 shares of the biotechnology company’s stock after purchasing an additional 222,347 shares during the quarter. Acadian Asset Management LLC owned about 1.41% of Conatus Pharmaceuticals worth $121,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 15.97% of the company’s stock.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Further Reading: Holder of Record
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.